◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

Monte Rosa Therapeutics, Inc.

CIK: 1826457 SIC: 2836
$123.67M
Revenue
$-38.63M
Net Income
-
Gross Margin
-43.83%
Op. Margin
$-158.07M
Free Cash Flow
Financial Statements Quarterly (10-Q)
Showing 7 of 14 quarterly reports available
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
+ Total Revenue $2.78M $12.77M $23.19M $84.93M $60.65M $9.22M $4.70M
Revenue Growth % (YoY) -95.4% 38.5% 394.0% nan% nan% nan% nan%
Operating Expenses $52.50M $45.74M $38.75M $40.89M $47.64M $35.74M $37.34M
Research & Development $41.98M $36.68M $30.65M $32.19M $38.87M $27.62M $28.05M
+ Operating Income $-49.72M $-32.98M $-15.55M $44.04M $13.00M $-26.53M $-32.64M
Operating Margin % -1787.7% -258.3% -67.1% 51.9% 21.4% -287.8% -695.3%
Other Income/Expense $3.64M $2.72M $4.46M $3.67M $2.60M $2.74M $2.58M
Income Before Tax $-46.08M $-30.26M $-11.10M $47.71M $15.60M $-23.79M $-30.06M
Income Tax Expense $59.00K $-3.18M $1.20M $822.00K $2.16M $71.00K $252.00K
+ Net Income $-46.13M $-27.08M $-12.29M $46.88M $13.44M $-23.86M $-30.31M
Net Margin % -1658.9% -212.1% -53.0% 55.2% 22.2% -258.9% -645.6%
Basic Shares Outstanding 826K 82.4M 82.2M 82.1M 2.7M 82.0M 71.2M
Diluted Shares Outstanding 128K 82.4M 82.2M 83.0M 2.7M 82.0M 71.2M
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Cash & Cash Equivalents $129.88M $208.34M $69.43M $78.53M $224.25M $125.58M $108.85M
Accounts Receivable - - - - - - $9.00M
Other Current Assets $4.48M $5.59M $6.50M $4.80M $5.12M $8.43M $5.85M
Total Current Assets $393.19M $401.82M $299.46M $332.28M $377.44M $251.21M $277.90M
Property Plant & Equipment $25.99M $27.60M $29.05M $29.34M $29.48M $31.44M $33.25M
Other Non-current Assets $148.00K $411.00K $445.00K $440.00K $115.00K $159.00K $209.00K
Total Assets $448.66M $459.84M $359.59M $393.20M $438.73M $315.08M $344.11M
Accounts Payable $3.55M $14.51M $5.58M $6.49M $17.21M $3.98M $6.47M
Accrued Liabilities $26.69M - - - $18.79M - -
Deferred Revenue $29.57M $24.79M $18.41M $32.58M $117.23M $18.92M $19.64M
Total Current Liabilities $64.21M $61.44M $41.85M $59.22M $156.95M $41.64M $42.35M
Total Liabilities $215.60M $214.00M $91.51M $118.04M $215.80M $109.62M $119.44M
Common Stock $7.00K $6.00K $6.00K $6.00K $6.00K $6.00K $6.00K
Retained Earnings $-477.21M $-431.08M $-404.00M $-391.70M $-438.59M $-452.02M $-428.17M
Total Stockholders Equity $233.06M $245.84M $268.08M $275.16M $222.94M $205.46M $224.67M
Total Liabilities & Equity $448.66M $459.84M $359.59M $393.20M $438.73M $315.08M $344.11M
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Net Income $-46.13M $-27.08M $-12.29M $46.88M $13.44M $-86.14M $-30.31M
Stock-based Compensation $4.31M $14.56M $10.19M $5.30M $4.47M $13.66M $9.38M
Change in Receivables - - - - - - $9.00M
Change in Payables $-10.61M $-3.10M $-11.98M $-10.87M $13.31M $-7.06M $-4.68M
Operating Cash Flow $-43.01M $20.22M $-80.21M $-45.49M $128.92M $-86.93M $-65.93M
Capital Expenditure $767.00K $3.93M $3.28M $1.59M $183.00K $3.81M $3.41M
Purchases of Investments $153.66M $223.02M $157.05M $138.01M $67.96M $162.40M $130.03M
Investing Cash Flow $-65.07M $-36.77M $-74.91M $-100.23M $-30.90M $-13.56M $-51.30M
Stock Issued - - - - - - -
Financing Cash Flow $29.62M $727.00K $379.00K $14.00K $608.00K $98.28M $98.27M
Net Change in Cash $-78.46M $-15.82M $-154.74M $-145.71M $98.63M $-2.20M $-18.97M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Total Revenue $12.77M - $120.89M -
Operating Expenses $45.74M - $125.38M -
Research & Development $36.68M - $99.52M -
Operating Income $-32.98M - $-4.49M -
Other Income/Expense $2.72M - $10.85M -
Income Before Tax $-30.26M - $6.35M -
Income Tax Expense $-3.18M - $-1.16M -
Net Income $-27.08M $-30.31M $7.51M -
Basic Shares Outstanding $82.40M - $82.25M -
Diluted Shares Outstanding $82.40M - $82.94M -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $208.34M $224.25M
Other Current Assets $5.59M $5.12M
Total Current Assets $401.82M $377.44M
Property Plant & Equipment $27.60M $29.48M
Other Non-current Assets $411.00K $115.00K
Total Assets $459.84M $438.73M
Accounts Payable $14.51M $17.21M
Deferred Revenue $24.79M $117.23M
Total Current Liabilities $61.44M $156.95M
Total Liabilities $214.00M $215.80M
Common Stock $6.00K $6.00K
Retained Earnings $-431.08M $-438.59M
Total Stockholders Equity $245.84M $222.94M
Total Liabilities & Equity $459.84M $438.73M
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-27.08M $-30.31M $7.51M -
Stock-based Compensation - - $14.56M -
Change in Payables - - $-3.10M -
Operating Cash Flow - - $20.22M -
Capital Expenditure - - $3.93M -
Purchases of Investments - - $223.02M -
Investing Cash Flow - - $-36.77M -
Stock Issued - - - -
Financing Cash Flow - - $727.00K -
Net Change in Cash - - $-15.82M -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-Q filings.

Quarterly data represents single quarter results (Q1-Q4). Some items may show year-to-date values if quarterly breakdown is unavailable.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...